CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA
interference (RNAi) therapeutics, today announced that the Company has
been selected for addition to the NASDAQ Biotechnology Index
(NASDAQ:NBI), effective upon market open on December 21, 2015.
The NASDAQ Biotechnology Index is designed to track the performance of a
set of securities listed on The NASDAQ Stock Market® that are
classified as either biotechnology or pharmaceutical according to the
Industry Classification Benchmark. These companies must meet eligibility
requirements, including minimum market capitalization, average daily
trading volume, and seasoning as a public company, among other criteria.
For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.
Dicerna Pharmaceuticals, Inc., is a
biopharmaceutical company focused on the discovery and development of
innovative treatments for rare, inherited diseases involving the liver
and for cancers that are genetically defined. The company is using its
proprietary RNA interference (RNAi) technology platform to build a broad
pipeline in these therapeutic areas. In both rare diseases and oncology,
Dicerna is pursuing targets that have been difficult to address using
conventional approaches, but where connections between targets and
diseases are well understood and documented. The company intends to
discover, develop and commercialize novel therapeutics either on its own
or in collaboration with pharmaceutical partners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151216006232/en/
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media